200 related articles for article (PubMed ID: 19843886)
1. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.
Nicolini FE; Mauro MJ; Martinelli G; Kim DW; Soverini S; Müller MC; Hochhaus A; Cortes J; Chuah C; Dufva IH; Apperley JF; Yagasaki F; Pearson JD; Peter S; Sanz Rodriguez C; Preudhomme C; Giles F; Goldman JM; Zhou W
Blood; 2009 Dec; 114(26):5271-8. PubMed ID: 19843886
[TBL] [Abstract][Full Text] [Related]
2. [Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
Wang J; Zhang Y; Zu Y; Li Z; Li M; Song Y
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):110-4. PubMed ID: 27014979
[TBL] [Abstract][Full Text] [Related]
3. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
[TBL] [Abstract][Full Text] [Related]
4. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
[TBL] [Abstract][Full Text] [Related]
5. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
6. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
[TBL] [Abstract][Full Text] [Related]
10. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.
Nicolini FE; Ibrahim AR; Soverini S; Martinelli G; Müller MC; Hochhaus A; Dufva IH; Kim DW; Cortes J; Mauro MJ; Chuah C; Labussière H; Morisset S; Roche-Lestienne C; Lippert E; Hayette S; Peter S; Zhou W; Maguer-Satta V; Michallet M; Goldman J; Apperley JF; Mahon FX; Marin D; Etienne G
Haematologica; 2013 Oct; 98(10):1510-6. PubMed ID: 23716543
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.
Nicolini FE; Basak GW; Soverini S; Martinelli G; Mauro MJ; Müller MC; Hochhaus A; Chuah C; Dufva IH; Rege-Cambrin G; Saglio G; Michallet M; Labussière H; Morisset S; Hayette S; Etienne G; Olavarria E; Zhou W; Peter S; Apperley JF; Cortes J
Blood; 2011 Nov; 118(20):5697-700. PubMed ID: 21926354
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Seymour JF; Kim DW; Rubin E; Haregewoin A; Clark J; Watson P; Hughes T; Dufva I; Jimenez JL; Mahon FX; Rousselot P; Cortes J; Martinelli G; Papayannidis C; Nagler A; Giles FJ
Blood Cancer J; 2014 Aug; 4(8):e238. PubMed ID: 25127392
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
14. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Pagnano KB; Bendit I; Boquimpani C; De Souza CA; Miranda EC; Zalcberg I; Larripa I; Nardinelli L; Silveira RA; Fogliatto L; Spector N; Funke V; Pasquini R; Hungria V; Chiattone CS; Clementino N; Conchon M; Moiraghi EB; Lopez JL; Pavlovsky C; Pavlovsky MA; Cervera EE; Meillon LA; Simões B; Hamerschlak N; Bozzano AH; Mayta E; Cortes J; Bengió RM;
Cancer Invest; 2015; 33(9):451-8. PubMed ID: 26288116
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
17. The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors.
Chien SH; Liu HM; Chen PM; Ko PS; Lin JS; Chen YJ; Lee LH; Hsiao LT; Chiou TJ; Gau JP; Yang MH; Liu CY
Hematol Oncol; 2020 Aug; 38(3):390-398. PubMed ID: 32011024
[TBL] [Abstract][Full Text] [Related]
18. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
19. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
Okabe S; Tauchi T; Ohyashiki K
Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
